Skip to content
Open access

AI-guided epitope engineering of a SARS-CoV-2 spike antigen for broad sarbecovirus neutralization

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 83 references
Medicine

TL;DR

These findings show that minimal, structure-guided epitope remodeling can enhance the presentation of conserved epitopes and improve antibody breadth, providing a generalizable framework for designing vaccines resilient to viral evolution and future pandemic threats.

Abstract

The rapid evolution of SARS-CoV-2 and the ongoing risk of zoonotic spillover highlight the need for vaccines that provide broad protection beyond strain-specific immunity. Here, we present a structure-guided, AI-enabled strategy for rational antigen design that enhances cross-reactive B-cell epitope recognition across betacoronaviruses. By integrating comparative sequence analysis with conformational epitope prediction, we identified conserved epitope hotspots within the Spike receptor-binding domain and introduced targeted motif-level substitutions into a SARS-CoV-2 BA.2 backbone. Engineered Spike immunogens, delivered as mRNA-lipid nanoparticle vaccines, elicited robust antibody responses in mice and demonstrated broad neutralizing activity against antigenically diverse SARS-CoV-2 variants, including BA.5 and XBB.1.5, as well as zoonotic sarbecoviruses. Selected designs reached neutralisation breadth comparable to an Omicron-adapted clinical benchmark for shared SARS-CoV-2 antigens, while extending neutralising activity to divergent zoonotic sarbecoviruses. These findings show that minimal, structure-guided epitope remodeling can enhance the presentation of conserved epitopes and improve antibody breadth, providing a generalizable framework for designing vaccines resilient to viral evolution and future pandemic threats.

Read PDF

Similar papers

Open access Oct 2026

Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses

The continuing evolution of SARS-CoV-2 variants of concern, and the increasing spillover potential of sarbecoviruses into the human population presents an important and urgent need to discover cross-reactive monoclonal antibodies (mAbs) for future therapeutic use and identify conserved neutralising epitopes that can be...

Ayush Upadhyay, J. Seow, Yilmaz Alguel et al. · 1 citation
Open access Sep 2026

Multi-epitope vaccine targeting SARS-CoV-2 omicron S and N proteins promotes enhanced immunity: a computational approach

Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the COVID-19 pandemic, which resulted in millions of deaths globally and had profound social, economic, and political consequences. Although effective vaccines and antiviral therapies have substantially reduced the global bu...

Xin-Yi Xu, Arslan Habib, Nai-Shuo Zhu · 0 citations
Open access Sep 2026

Antigenic remodeling of the SARS-CoV-2 Spike N-terminal domain links sequence variability to structural reorganization of a neutralizing antibody supersite

Introduction The N-terminal domain (NTD) of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike harbors a neutralizing antibody supersite and is a recurrent site of antigenic change. However, how sequence variability across pre- and post-vaccination immune landscapes reshapes antibody recognition rem...

J. S. Ardisson, Brena Ramos Athaydes, Mariane Vedovatti Monfardini Sagrillo et al. · 0 citations
Open access Sep 2026

Chimeric SARS-CoV-2 vaccine vectors stably incorporating the functional glycoprotein of VSV

Stable genetic incorporation and display of a functional heterologous glycoprotein into a SARS-CoV-2 virion are demonstrated, supporting use of the ΔE SARS-CoV-2 backbone as a potential platform for viral vector engineering and heterologous antigen delivery.

E. Kipfer, Jacob Schön, Mohamed Chami et al. · 0 citations
Open access Oct 2026

Variant escape site mapping and characterization of SARS-CoV-2 nucleocapsid rapid antigen test antibodies

ABSTRACT Rapid antigen tests (RATs) were a critical tool for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the height of the pandemic, but their performance depends on antibodies that remain robust to viral evolution. Since most commercial RATs target the viral nucleocapsid pr...

Alasdair D. Keith, Meredith M. Keen, Filipp Frank et al. · 1 citation
Open access Sep 2026

mRNA Vaccines Targeting the Conserved SARS-CoV-2 Fusion Machinery Elicit Cross-Variant and Robust Immunity

Background/Objectives: Despite the gradual waning of global interest in SARS-CoV-2, the continued evolution and emergence of viral variants underscore the need for broadly protective vaccines. Vaccines targeting the highly mutable S1 subunit of the spike protein have shown limited breadth of protection, whereas conserv...

Jun Li, Ke-Meng Li, Shu-Heng Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.